Yinjia Biosciences

Yinjia Biosciences is a private China-based protein technology and biopharma tools company founded in 2020. The company operates a protein-centered platform focused on recombinant protein raw materials, enzymes, bioprocess quality-control reagents, and diagnostic products serving drug discovery, vaccines, cell therapy, ADC development, and molecular diagnostics. Its platform combines protein engineering with computer simulation, AI-assisted development, and Cell Free Protein Selective (CFPS) technology. Yinjia markets a broad catalog that includes T7 RNA polymerase, recombinant TNFalpha, recombinant trypsin, hyaluronidase, restriction enzymes, and Protein A residual ELISA kits, and it has built laboratory and GMP pilot capabilities in Shanghai, Suzhou, and Beijing. Rather than being a therapeutics developer with a disclosed clinical pipeline, it appears to generate revenue from research tools, core raw materials, and diagnostics-related products and services for life science customers.